Sign up to access all valuation multiples
SANUWAVE Health Inc is an ultrasound and shock wave technology company using patented systems of noninvasive, high-energy, acoustic shock waves or low-intensity and non-contact ultrasound for regenerative medicine and other applications. The company's focus is regenerative medicine utilizing noninvasive, acoustic shock waves or ultrasound to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's two primary systems are UltraMIST and PACE. UltraMIST and PACE are the only two Food and Drug Administration (FDA) approved directed energy systems for wound healing.
2004
46
LTM Revenue $44.3M
LTM EBITDA $13.3M
$272M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of December 2025, SANUWAVE Health reported last 12-month revenue of $44.3M and EBITDA of $13.3M.
In the same period, SANUWAVE Health generated $34.6M in LTM gross profit and $7.2M in net income.
See SANUWAVE Health valuation multiples based on analyst estimatesIn the most recent fiscal year, SANUWAVE Health reported revenue of $32.6M and EBITDA of -$16.6M.
SANUWAVE Health expects next 12-month revenue of XXX and NTM EBITDA of XXX
See SANUWAVE Health valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $44.3M | XXX | $32.6M | XXX | XXX | XXX |
| Gross Profit | $34.6M | XXX | $24.6M | XXX | XXX | XXX |
| Gross Margin | 78% | XXX | 75% | XXX | XXX | XXX |
| EBITDA | $13.3M | XXX | -$16.6M | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | -51% | XXX | XXX | XXX |
| EBIT | $6.3M | XXX | $5.4M | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $7.2M | XXX | -$31.4M | XXX | XXX | XXX |
| Net Margin | 16% | XXX | -96% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $15.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
SANUWAVE Health has current market cap of $257M, and EV of $272M.
As of December 31, 2025, SANUWAVE Health's stock price is $30.
See SANUWAVE Health trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $272M | $257M | XXX | XXX | XXX | XXX | $0.42 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialSANUWAVE Health's trades at 8.3x EV/Revenue multiple, and -16.4x EV/EBITDA.
See valuation multiples for SANUWAVE Health and 15K+ public compsAs of December 31, 2025, SANUWAVE Health has market cap of $257M and EV of $272M.
Equity research analysts estimate SANUWAVE Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SANUWAVE Health has a P/E ratio of 35.5x.
| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $257M | XXX | $257M | XXX | XXX | XXX |
| EV (current) | $272M | XXX | $272M | XXX | XXX | XXX |
| EV/Revenue | 6.1x | XXX | 8.3x | XXX | XXX | XXX |
| EV/EBITDA | 20.4x | XXX | -16.4x | XXX | XXX | XXX |
| EV/EBIT | 43.0x | XXX | 50.1x | XXX | XXX | XXX |
| EV/Gross Profit | 7.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 35.5x | XXX | -8.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 138.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSANUWAVE Health's last 12 month revenue growth is 31%
SANUWAVE Health's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.4M for the same period.
SANUWAVE Health's rule of 40 is -14% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
SANUWAVE Health's rule of X is 108% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for SANUWAVE Health and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 31% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | -51% | XXX | XXX | XXX |
| EBITDA Growth | 37% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -14% | XXX | -19% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 108% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 59% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SANUWAVE Health acquired XXX companies to date.
Last acquisition by SANUWAVE Health was XXXXXXXX, XXXXX XXXXX XXXXXX . SANUWAVE Health acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was SANUWAVE Health founded? | SANUWAVE Health was founded in 2004. |
| Where is SANUWAVE Health headquartered? | SANUWAVE Health is headquartered in United States of America. |
| How many employees does SANUWAVE Health have? | As of today, SANUWAVE Health has 46 employees. |
| Who is the CEO of SANUWAVE Health? | SANUWAVE Health's CEO is Mr. Morgan C. Frank. |
| Is SANUWAVE Health publicy listed? | Yes, SANUWAVE Health is a public company listed on NAS. |
| What is the stock symbol of SANUWAVE Health? | SANUWAVE Health trades under SNWV ticker. |
| When did SANUWAVE Health go public? | SANUWAVE Health went public in 2008. |
| Who are competitors of SANUWAVE Health? | Similar companies to SANUWAVE Health include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of SANUWAVE Health? | SANUWAVE Health's current market cap is $257M |
| What is the current revenue of SANUWAVE Health? | SANUWAVE Health's last 12 months revenue is $44.3M. |
| What is the current revenue growth of SANUWAVE Health? | SANUWAVE Health revenue growth (NTM/LTM) is 31%. |
| What is the current EV/Revenue multiple of SANUWAVE Health? | Current revenue multiple of SANUWAVE Health is 6.1x. |
| Is SANUWAVE Health profitable? | Yes, SANUWAVE Health is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of SANUWAVE Health? | SANUWAVE Health's last 12 months EBITDA is $13.3M. |
| What is SANUWAVE Health's EBITDA margin? | SANUWAVE Health's last 12 months EBITDA margin is 30%. |
| What is the current EV/EBITDA multiple of SANUWAVE Health? | Current EBITDA multiple of SANUWAVE Health is 20.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
